Suchergebnisse - Alexander E. Perl

Treffer weiter einschränken
  1. 1
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML von Alexander E. Perl

    Veröffentlicht 2017
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Availability of FLT3 inhibitors: how do we use them?

    Availability of FLT3 inhibitors: how do we use them? von Alexander E. Perl

    Veröffentlicht 2019
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    The role of targeted therapy in the management of patients with AML

    The role of targeted therapy in the management of patients with AML von Alexander E. Perl

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Gilteritinib: potent targeting of FLT3 mutations in AML

    Gilteritinib: potent targeting of FLT3 mutations in AML von Mark J. Levis, Alexander E. Perl

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Advances in patient care through increasingly individualized therapy

    Advances in patient care through increasingly individualized therapy von Courtney D. DiNardo, Alexander E. Perl

    Veröffentlicht 2019
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

    Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemothera... von Alexander E. Perl, Margaret Kasner, Doris Shank, Selina M. Luger, Martin Carroll

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

    Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia von Pamela J. Sung, Mayumi Sugita, Holly K. Koblish, Alexander E. Perl, Martin Carroll

    Veröffentlicht 2019
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

    Molecular profile of <i>FLT3</i>-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib von Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

    Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations von Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study von Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Veröffentlicht 2019
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome von Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Veröffentlicht 2013
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

    Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia von Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne Qualtieri, Christopher D. Watt, Jennifer J.D. Morrissette, Martin Carroll, Alexander E. Perl

    Veröffentlicht 2019
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia

    Harnessing the benefits of available targeted therapies in acute myeloid leukaemia von Hagop M. Kantarjian, Nicholas J. Short, Courtney D. DiNardo, Eytan M. Stein, Naval Daver, Alexander E. Perl, Eunice S. Wang, Andrew H. Wei, Martin S. Tallman

    Veröffentlicht 2021
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  14. 14
    A robust xenotransplantation model for acute myeloid leukemia

    A robust xenotransplantation model for acute myeloid leukemia von P V Sanchez, Robin Perry, Jean‐Emmanuel Sarry, Alexander E. Perl, Kathleen M. Murphy, Cezary Swider, Adam Bagg, John Choi, Jaclyn A. Biegel, Gwenn Danet-Desnoyers, Martin Carroll

    Veröffentlicht 2009
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

    Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML von Jorge E. Cortés, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220

    A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220 von Panpan Hou, Chao Wu, Yuchen Wang, Rui Qi, Dheeraj Bhavanasi, Zhixiang Zuo, Cédric Dos Santos, Shuliang Chen, Yu Chen, Hong Zheng, Hong Wang, Alexander E. Perl, Deyin Guo, Jian Huang

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations von Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason E. Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

    Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL von Christian Hurtz, Gerald Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne W. Lehman, Yong Li, Asen Bagashev, Bryan Manning, Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian

    Veröffentlicht 2020
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML von Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) von Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: